Acumen Pharmaceuticals
Most recent annual filing: 2026-01-15
- Sabirnetug (ACU193) IV Ph2 toplineLate 2026Sabirnetug (ACU193) IV Ph2 topline, Late 2026, thesis-defining
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
ACU301
ACU401
Technology platforms
EBD · JCR Pharmaceuticals
Enhanced Brain Delivery — transferrin receptor (TfR)-mediated BBB-penetrating bispecific antibody platform developed in collaboration with JCR Pharmaceuticals; focus area: Alzheimer's disease. Lead candidate ACU401 demonstrated up to 40-fold greater frontal cortex exposure in non-human primates with subcutaneous absorption and no hematological safety signals.
Targets: amyloid beta oligomers, AβOs, transferrin receptor, TfR, hTfR
ENHANZE · Halozyme
Halozyme's proprietary drug delivery technology used for subcutaneous formulation of sabirnetug; focus area: Alzheimer's disease.
Biotech Distilled coverage (5)
- 2026-08-13 UPDATE: Acumen Pharmaceuticals (ABOS) - The Dilution Gap Re-Opens
- 2026-07-15 UPDATE: Acumen Pharmaceuticals (ABOS) - The EBD Data Just Got Better 🔒 Paid
- 2026-03-28 UPDATE: Acumen Pharmaceuticals (ABOS) - 10-K Drop: The Dilution Gap is Officially Closed 🔒 Paid
- 2026-03-21 UPDATE: Acumen Pharmaceuticals (ABOS) - The Dilution Gap Closes, Smart Money Enters, and the Science Delivers 🔒 Paid
- 2026-02-18 Acumen Pharmaceuticals (ABOS): Scientific Deep Dive for Sabirnetug 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.